Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) EBITDA (2016 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed EBITDA for 16 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 14.72% to -$1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.1 million, a 8.04% decrease, with the full-year FY2024 number at -$5.7 million, down 2.2% from a year prior.
  • EBITDA was -$1.3 million for Q3 2025 at Creative Medical Technology Holdings, down from -$1.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$303944.0 in Q1 2021 to a low of -$6.3 million in Q4 2022.
  • A 5-year average of -$1.5 million and a median of -$1.3 million in 2025 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 355.86% in 2021, then soared 71.78% in 2023.
  • Creative Medical Technology Holdings' EBITDA stood at -$1.5 million in 2021, then plummeted by 326.28% to -$6.3 million in 2022, then skyrocketed by 71.78% to -$1.8 million in 2023, then fell by 6.43% to -$1.9 million in 2024, then surged by 32.49% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CELZ's EBITDA are -$1.3 million (Q3 2025), -$1.3 million (Q2 2025), and -$1.7 million (Q1 2025).